A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Name: A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Published: 2018
License: Public Domain

Novartis Pharmaceuticals · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

chronic spontaneous urticaria, anti-ige, csu, hives severity score, itch severity score, urticaria activity score, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Related documents